Efficacy and Safety of Oral Administration of the Plant-based Complex Actitan-F in the Management of Chronic Paediatric Diarrhoea: a Double-blind, Placebo-controlled, Parallel-group Investigation

The goal of the study is to investigate the efficacy and safety of Lenodiar Pediatric (product under investigation) for the treatment of Chronic Diarrhoea (functional or post-infective diarrhoea) in children aged 1-5 years old, through a randomized, double blind, placebo-controlled clinical investigation

开始日期2023-07-10

申办/合作机构

Aboca S.p.A. Società Agricola

[+1]

NCT05016024 / CompletedN/A

A Randomized, Cross-over, Placebo-Controlled, Double-Blind Clinical Trial on the Efficacy and Safety of Oral Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in the Treatment of Irritable Bowel Syndrome

This study is aimed to investigate the efficacy and safety of Colilen IBS, a Medical Device made of natural substances, even when taken in addition to other therapies, for the treatment of Irritable Bowel Syndrome.

开始日期2021-08-05

申办/合作机构

Aboca S.p.A. Società Agricola

[+1]

NCT02076672 / Completed临床2期IIT

Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (The ABOCA Phase II Trial)

This is a single-arm phase II trial to assess the biological activity (in a sub-cohort using a Simon two-stage Phase II design) and toxicity of Artichoke Whole Phytocomplex Concentrate (WPC). The objective of the study is to explore the potential for a non-toxic phytocomplex extract from the artichoke plant as a chemoprevention agent.

开始日期2019-11-05

申办/合作机构

Ontario Clinical Oncology Group

[+1]

100 项与 Aboca S.p.A. Società Agricola 相关的临床结果

登录后查看更多信息

0 项与 Aboca S.p.A. Società Agricola 相关的专利（医药）

登录后查看更多信息

项与 Aboca S.p.A. Società Agricola 相关的文献（医药）

2022-09-01·Heliyon

Wheat germ oil vitamin E cytoprotective effect and its nutrigenomics signature in human hepatocyte lipotoxicity

Article

作者: Bartolini, Desirée ; Lucci, Jacopo ; Galli, Francesco ; Rende, Mario ; Stabile, Anna Maria ; Marcantonini, Giada ; Guerrini, Angela ; Zatini, Linda ; Frammartino, Tiziana ; Garetto, Stefano ; Migni, Anna ; Marinelli, Rita

Wheat germ oil (WGO) is rich in α-tocopherol (vitamin E, VE), a vitamin that has long been suggested to exert hepatoprotective effects. In this study, this function of WGO-VE and its transcriptomics fingerprint were investigated in comparison with RRR-α-tocopherol and all-rac-α-tocopherol (nVE and sVE, respectively), in human liver cells treated with oleic acid (OA) to develop steatosis and lipotoxicity. Used in chemoprevention mode, all the VE formulations afforded significant reduction of the OA-induced steatosis and its consequent impact on lipotoxicity indicators, including ROS production and efflux (as H₂O₂), and apoptotic and necrotic cell death. A trend toward a better control of lipotoxicity was observed for WGO-VE and nVE compared to sVE. Gene microarray data demonstrated that these effects of VE formulations were associated with significantly different responses of the cellular transcriptome to compensate for the modifications of OA treatment, including the downregulation of cellular homeostasis genes and the induction of genes associated with defects of liver cell metabolism, fibrosis and inflammation, liver disease and cancer. Ingenuity Pathway Analysis data showed that WGO-VE modulated genes associated with liver carcinogenesis and steatosis, whereas nVE modulated genes involved in liver cell metabolism and viability biofunctions; sVE did not significantly modulate any gene dataset relevant to such biofunctions. In conclusion, WGO-VE prevents lipotoxicity in human liver cells modulating genes that differ from those affected by the natural or synthetic forms of pure VE. These differences can be captured by precision nutrition tools, reflecting the molecular complexity of this VE-rich extract and its potential in preventing specific cues of hepatocellular lipotoxicity.

2022-01-01·Acta diabetologica3区 · 医学

Protective effects of Stevia rebaudiana extracts on beta cells in lipotoxic conditions

3区 · 医学

Article

作者: Lacerenza, Serena ; Bugliani, Marco ; Tavarini, Silvia ; Ronci, Maurizio ; Tesi, Marta ; Tondi, Silvia ; Angelini, Luciana G ; Maidecchi, Anna ; Grano, Francesca ; Marchetti, Piero ; Giusti, Laura

Abstract:

Aims:

Stevia rebaudiana Bertoni leaf extracts have gained increasing attention for their potential protection against type 2 diabetes. In this study, we have evaluated the possible beneficial effects of Stevia rebaudiana leaf extracts on beta-cells exposed to lipotoxicity and explored some of the possible mechanisms involved.

Methods:

Extracts, deriving from six different chemotypes (ST1 to ST6), were characterized in terms of steviol glycosides, total phenols, flavonoids, and antioxidant activity. INS-1E beta cells and human pancreatic islets were incubated 24 h with 0.5 mM palmitate with or without varying concentrations of extracts. Beta-cell/islet cell features were analyzed by MTT assay, activated caspase 3/7 measurement, and/or nucleosome quantification. In addition, the proteome of INS-1E cells was assessed by bi-dimensional electrophoresis (2-DE).

Results:

The extracts differed in terms of antioxidant activity and stevioside content. As expected, 24 h exposure to palmitate resulted in a significant decrease of INS-1E cell metabolic activity, which was counteracted by all the Stevia extracts at 200 μg/ml. However, varying stevioside only concentrations were not able to protect palmitate-exposed cells. ST3 extract was also tested with human islets, showing an anti-apoptotic effect. Proteome analysis showed several changes in INS-1E beta-cells exposed to ST3, mainly at the endoplasmic reticulum and mitochondrial levels.

Conclusions:

Stevia rebaudiana leaf extracts have beneficial effects on beta cells exposed to lipotoxicity; this effect does not seem to be mediated by stevioside alone (suggesting a major role of the leaf phytocomplex as a whole) and might be due to actions on the endoplasmic reticulum and the mitochondrion.

2018-10-01·Cancer letters

Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines

Article

作者: Pulito, Claudio ; Muti, Paola ; Korita, Etleva ; Serra, Massimo ; Finch-Edmondson, Megan ; Sudol, Marius ; Strano, Sabrina ; Ferraiuolo, Maria ; Maidecchi, Anna ; Blandino, Giovanni ; Donzelli, Sara

Osteosarcoma (OS) is the most aggressive type of primary solid tumor that develops in bone. Whilst conventional chemotherapy can improve survival rates, the outcome for patients with metastatic or recurrent OS remains poor, so novel treatment agents and strategies are required. Research into new anticancer therapies has paved the way for the utilisation of natural compounds as they are typically less expensive and less toxic compared to conventional chemotherapeutics. Previously published works indicate that Agave exhibits anticancer properties, however potential molecular mechanisms remain poorly understood. In the present study, we investigate the anticancer effects of Agave leaf extract in OS cells suggesting that Agave inhibits cell viability, colony formation, and cell migration, and can induce apoptosis in OS cell lines. Moreover, Agave sensitizes OS cells to cisplatin (CDDP) and radiation, to overcome chemo- and radio-resistance. We demonstrate that Agave extract induces a marked decrease of Yes Associated Protein (YAP) and Tafazzin (TAZ) mRNA and protein expression upon treatment. We propose an initial mechanism of action in which Agave induces YAP/TAZ protein degradation, followed by a secondary event whereby Agave inhibits YAP/TAZ transcription, effectively deregulating the Nuclear Factor kappa B (NF-κB) p65:p50 heterodimers responsible for transcriptional induction of YAP and TAZ.

项与 Aboca S.p.A. Società Agricola 相关的新闻（医药）

2017-08-12

·BioPortfolio

Constipation Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

DelveInsight's, Constipation Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Constipation. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Constipation. This report provides information on the therapeutic development for Constipation, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report. The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. Forest Labs and Ironwood Pharmaceuticals;AstraZeneca;Shionogi;Synergy Pharmaceuticals;Enterin Inc.;Kyowa Kirin Pharmaceutical Development Ltd;RaQualia Pharma Inc;AstraZeneca;KGK Synergize Inc.;Sucampo Pharmaceuticals Inc.;Ardelyx;Mundipharma China Pharmaceutical Co. Ltd;Purdue Pharma LP;Aboca Spa Societa' Agricola;Merck Sharp Dohme Corp.;Admescope Ltd;Yakult Constipation Pipeline Drugs Constipation Pipeline Assessment Constipation Pipeline Analysis Constipation Drugs under Development Constipation Discovery drugs Constipation Preclinical drugs Constipation Phase I drugs Constipation Phase II drugs Constipation Phase III Pipeline Drugs Assessment Constipation Preregistration drugs Constipation Molecules in pipeline

100 项与 Aboca S.p.A. Società Agricola 相关的药物交易

登录后查看更多信息

100 项与 Aboca S.p.A. Società Agricola 相关的转化医学

登录后查看更多信息